MannKind Corporation (MNKD) announced positive topline results from its Phase 1b INFLO-1 study of nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis (IPF), meeting its primary objective of demonstrating safety and tolerability.
The randomized, double-blind, placebo-controlled trial enrolled 27 patients across 10 U.S. sites and tested two multiple-ascending dose regimens over seven days. Results showed no serious adverse events, no gastrointestinal side effects, no bronchospasm, and no treatment discontinuations. Spirometry parameters were comparable between nintedanib DPI and placebo. Most patients experienced no cough, and when cough occurred, it was mild, transient, and resolved without intervention.
Chief Executive Officer Michael Castagna highlighted that across Phase 1a and 1b studies, more than 700 inhalations have been administered, including nearly 450 in IPF patients, with cough not posing a meaningful barrier to treatment.
The Phase 1a program in healthy volunteers has previously established a favorable safety profile, with rapid absorption and dose-proportional plasma concentrations consistent with deep-lung delivery.
MannKind is now advancing to its global Phase 2 INFLO-2 trial, which is actively enrolling patients. Additional data from INFLO-1 will be presented at a future conference.
MNKD has traded between $2.23 and $6.51 over the past year. The stock closed Tuesday's trading at $3.91, down 1.01%. In pre-market trading the stock is trading at $3.94, up 0.77%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.